This strategy enables Pfizer to maintain a strong foothold in the generic drug market while also protecting its revenue ...

South Korean pharmaceutical and biotechnology companies are on edge as U.S. President Donald Trump signals the introduction ...

The US OTC drugs market thrives, driven by increasing self-medication trends, diverse product offerings, and growing health ...

Teva Pharmaceuticals Industries, Akorn Inc., Mylan N.V., Mallinckrodt, and Sandoz International GmbH Lead the Competition ...

The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key ...

Sandoz recently announced a $275 million settlement with its subsidiary Fougera Pharmaceuticals, to resolve allegations of ...

Trade groups representing pharma distributors and generic/biosimilar industries express concerns over potential tariffs on ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with ...

Both drugs are set to lose protection from a key U.S. patent in February, according to Amgen’s most recent annual report. While Sandoz appears poised to hit the scene with its biosimilars first ...